News

Full-year net revenue is expected to be between $6.77 billion and $6.92 billion, compared to the company's previous estimate of $6.63 billion to $6.88 billion. Fourth quarter net revenue is expected to be between $1.8 billion and $1.95 billion, while analysts expect $1.8 billion.

According to the agreement, Quest Diagnostics will provide professional sample collection services for Insight Molecular Diagnostics Inc. This collaboration aims to leverage Quest Diagnostics' extensive network and expertise in diagnostic services to support the business operations of Insight Molecular Diagnostics Inc. The relevant arrangements have been officially documented.

This forecast highlights the company's confidence in its medium- to long-term profitability, representing a significant leap from its current financial performance. The projected range reflects management's optimistic assessment of the effectiveness of its business expansion strategies, including the continued growth of its equipment leasing business and the deep development of the second-hand equipment market. Through digital service upgrades and supply chain optimization, the company is striving to enhance asset turnover efficiency, injecting new momentum into profit growth. Notably, the adjusted EBITDA indicator excludes the impact of non-recurring items, providing a more accurate reflection of the company's core operational quality. If actual performance reaches the upper end of the guidance, it would represent a compound growth rate of over 40% compared to the 2023 financial report data, demonstrating its profitability resilience in a high interest rate environment.